Inclusion Criteria:

          -  Patients must have histologically proven GBM from the initial resection.

          -  Patients must have a life expectancy > 16 weeks. Patients must have a Karnofsky
             performance status of ≥ 60 or ECOG 0 - 2

          -  Patient's requirement for dexamethasone should be ≤ 4mg daily or a stable dose at
             enrollment.

          -  Patients must have adequate bone marrow, hepatic and renal function and hemoglobin and
             the test musts be performed within 14 days prior to study Day 1.

          -  Highly effective contraception for both male and female subjects if the risk of
             conception exists.

        Exclusion Criteria:

          -  Known history of autoimmune disorder except diabetes mellitus type 1, vitiligo or
             hypothyroidism only requiring hormone replacement

          -  Patients who have received any other therapeutic investigational agent within 30 days
             of enrollment with the exception of the personalized MTA vaccine (NCT03223103) that
             can be continued throughout the study.

          -  Patients who have received any other therapeutic investigational agent within 30 days
             of enrollment or prior

          -  Prior placement of intracavitary BCNU-impregnated wafers (Gliadel).

          -  Prior treatment with checkpoint inhibitors, CTL-4 antibody or other immunotherapy
             agents

          -  Presence of any other active malignancy or prior history of malignancy, except for:
             basal cell carcinoma of the skin, cervical carcinoma in situ, early stage prostate
             carcinoma not requiring active treatment.

          -  Prior organ transplantation, including allogeneic stem cell transplantation

          -  Significant acute or chronic infections including, among others: HIV, AIDS, HBV

          -  Pregnancy or lactation

        Contact site for full inclusion/exclusion list.